Figure 3.
Figure 3. Recurrent abnormalities at relapse vs pretreatment. (A) Schematic representation of the paired samples used for this analysis: lavender for preibrutinib (pre-ibr) and red for relapse sample. (B) Venn diagrams comparing the genetic lesions in the paired pre-ibr and relapse (Rel) samples of each patient. (C) Bar graph summarizing the total number of genetic lesions identified in the pre-ibr and relapse samples. (D) Table summarizing the number of genetic lesions gained in the relapse samples. The line separates patients with RT from those without RT. (E) List of relapse-specific genes for each patient. Colored boxes indicate recurrent genes. *BTK found at low allele frequency (Table 2 also lists emerging minor clones). LOH, loss of heterozygosity.

Recurrent abnormalities at relapse vs pretreatment. (A) Schematic representation of the paired samples used for this analysis: lavender for preibrutinib (pre-ibr) and red for relapse sample. (B) Venn diagrams comparing the genetic lesions in the paired pre-ibr and relapse (Rel) samples of each patient. (C) Bar graph summarizing the total number of genetic lesions identified in the pre-ibr and relapse samples. (D) Table summarizing the number of genetic lesions gained in the relapse samples. The line separates patients with RT from those without RT. (E) List of relapse-specific genes for each patient. Colored boxes indicate recurrent genes. *BTK found at low allele frequency (Table 2 also lists emerging minor clones). LOH, loss of heterozygosity.

Close Modal

or Create an Account

Close Modal
Close Modal